Ultrasound-guided Peripheral Intravenous Catheter Placement in an Oncologic Emergency Department - a Prospective, Randomized Controlled Trial of Catheter Lengths
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 400
- 试验地点
- 2
- 主要终点
- Safety and adverse events (AEs)
研究概览
简要总结
To learn about the effects of the length of the catheter on the failure and success rate of USIV placement.
详细描述
Primary Objectives:
- The rate of catheter failure, defined as removal of the catheter for any reason other than "Care Complete" (i.e. a composite of removal due to "infiltration," "leaking," "catheter damage," "occlusion"), by day 10.
Secondary Objectives:
- Time from catheter placement to removal (i.e. survival or dwell time).
- Per catheter length rate of failure analysis
- Rate of repeat catheterization
- Rate of infection
- Rate of thrombosis
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age > 18 years old.
- •Provision of signed and dated informed consent form.
- •Predetermined to have difficult IV access necessitating USIV placement
- •Expected admission to hospital with anticipated stay > 48 hours (per discussion with treating physician).
排除标准
- •Expected/anticipated discharge disposition from the ACCC (per discussion with treating physician).
- •Inability to give informed consent.
- •Pregnant women.
- •Non-English speaking participants.
研究组 & 干预措施
Group A
Participants will receive a catheter that is up to 1.75 inches long based on what the nurse thinks is best for you.
干预措施: Introcan Safety IV Catheter (Device)
Group B
Participants will receive a catheter that is either 1.75 or 2.5 inches long based on what the nurse thinks is best for you.
干预措施: Introcan Safety IV Catheter (Device)
结局指标
主要结局
Safety and adverse events (AEs)
时间窗: Through study completion; an average of 1 year.
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
次要结局
未报告次要终点